Clinical trials: leucovorin calcium
Lymphoma
Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell or bone marrow transplantation may allow the doctor to give…
- Trial name
- NCT00004231
- Testing
- aldesleukin, filgrastim, recombinant interferon alfa
- Where
- United States
- Sponsor
- Northwestern University
Colorectal Cancer, Metastatic Cancer
Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- ERBIFORT (NCT00557102)
- Testing
- cetuximab, filgrastim, fluorouracil
- Where
- France
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute, France
Colorectal Cancer
Erlotinib, Modified FOLFOX6, and Bevacizumab as First-Line Therapy Metastatic Colorectal Cancer
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as oxaliplatin, leucovorin, and fluorouracil, work in different ways to stop the…
- Trial name
- NCT00118261
- Testing
- bevacizumab, erlotinib hydrochloride, fluorouracil
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Case Comprehensive Cancer Center
Colorectal Cancer
MRI in Predicting Response in Patients Receiving Combination Chemotherapy and Bevacizumab For Advanced or Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00602329
- Testing
- bevacizumab, fluorouracil, leucovorin calcium
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Colon Cancer
CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
Colon cancer is one of the most common malignant tumors with an increasing incidence rate in China. Surgical resection is still the main treatment for colon cancer at present.
- Trial name
- REVISE (NCT06242418)
- Testing
- FOLFOXIRI, XELOX
- Where
- 9 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Pancreas Cancer
Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
This is an single-center, prospective, open-label clinical trial, to explore the safty and efficacy of combination of Bortezomib, Sindilizumab, and mFOLFIRINOX Chemotherapy (oxaliplatin, fluorouracil, irinotecan, leucovorin) in…
- Trial name
- CISPD-7 (NCT06572813)
- Testing
- Bortezomib Injection, Sintilimab, mFOLFIRINOX
- Where
- China
- Volunteers
- 63 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
AIDS-Related-Primary Central Nervous System Lymphoma
Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma
This study will investigate the use of chemotherapy plus highly active antiretroviral therapy (HAART) in patients with Acquired Immunodeficiency Syndrome (AIDS)-related primary brain lymphoma.
- Trial name
- NCT00267865
- Testing
- Methotrexate, Rituximab, Leucovorin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer
A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer
The goal of this clinical trial is to evaluate the preliminary safety and efficacy of SC0191 as single agent or in combination with bevacizumab or 5-FU/LV in advanced colorectal cancer.
- Trial name
- NCT06363552
- Testing
- SC0191, SC0191 + Bevacizumab, SC0191 + 5-FU/LV
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Tianshu Liu
Colorectal Cancer
Leucovorin and Fluorouracil With or Without SU5416 in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. SU5416 may stop the growth of colorectal cancer by stopping blood flow to the tumor.
- Trial name
- NCT00004252
- Testing
- fluorouracil, leucovorin calcium, semaxanib
- Where
- 26 sites in United States
- Sponsor
- Pfizer
Colorectal Cancer, Liver Metastases
Cetuximab+mFOLFOX6 VS. mFOLFOX6 Alone in RAS/BRAF Wild Type Patients With High-Risk Resectable CRLM
For patients with initially resectable colorectal cancer liver metastases who have high-risk factors, neoadjuvant therapy is currently considered a consensus approach.
- Trial name
- NCT05948072
- Testing
- mFOLFOX6 + Cetuximab, mFOLFOX 6
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Fudan University
Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum
Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer
This phase II trial studies how well bevacizumab, fluorouracil, leucovorin calcium, and oxaliplatin before surgery works in treating patients with stage II-III rectal cancer.
- Conditions
- Mucinous Adenocarcinoma of the Rectum, Signet Ring Adenocarcinoma of the Rectum, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer
- Trial name
- NCT01871571
- Testing
- bevacizumab, oxaliplatin, leucovorin calcium
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Southern California
Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
Riluzole in Combination With mFOLFOX6 and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
This phase I trial is to find out the best dose, possible benefits, and/or side effects of riluzole and how well it works in combination with standard of care mFOLFOX6 and bevacizumab in treating patients with colorectal cancer…
- Conditions
- Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8
- Trial name
- NCT04761614
- Testing
- Bevacizumab, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Ning Jin
Pancreatic Cancer
Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer
In this study, Adebrelimab combined with NALIRIFOX conversion therapy was performed in subjects with locally advanced pancreatic cancer to evaluate the efficacy and safety of conversion therapy with immunotherapy combined with…
- Trial name
- NCT06475326
- Testing
- Adebrelimab, Oxaliplatin 100 MG, Irinotecan liposome
- Where
- China
- Volunteers
- 87 people
- Sponsor
- Fudan University
Intrahepatic Cholangiocarcinoma
HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma
Primary liver cancer is the sixth most common cancer worldwide, including hepatocellular carcinoma and intrahepatic cholangiocarcinoma, of which intrahepatic cholangiocarcinoma accounts for 10%-15%.
- Trial name
- NCT05290116
- Testing
- HAIC Combined with Tislelizumab and Apatinib
- Where
- China
- Volunteers
- 17 people
- Sponsor
- Yunfei Yuan
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
This phase II clinical trial is studying how well giving combination chemotherapy and bevacizumab with or without RO4929097 works in treating patients with metastatic colorectal cancer.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer
- Trial name
- NCT01270438
- Testing
- FOLFOX regimen, gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab
- Where
- 3 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
This randomized, multi-center, active-controlled, open-label, parallel-group study will investigate the efficacy and safety of biomarker-driven maintenance treatment for first-line mCRC.
- Trial name
- MODUL (NCT02291289)
- Testing
- Cetuximab, FOLFOX induction regimen, Fluoropyrimidine (5-FU/LV or capecitabine)
- Where
- 154 sites in Argentina, Belgium and 21 more
- Volunteers
- 1,044 people
- Sponsor
- Hoffmann-La Roche
Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC)
To Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
The goal of this interventional clinical study is to learn the safety and preliminary efficacy of XH001 injection (Personalized mRNA tumor neoantigen vaccine) combined with standard adjuvant treatment in treating patients with…
- Conditions
- Biliary Cancer (Cholangiocarcinoma, Gall Bladder Cancer), Pancreatic Ductal Adenocarcinoma (PDAC), Hepatocellular Carcinoma (HCC), Gastric Cancer (GC)
- Trial name
- NCT07594964
- Testing
- XH001 Injection, mFOLFIRINOX Treatment Regimen
- Where
- 2 sites in China
- Volunteers
- 48 people
- Sponsor
- Shenzhen Xinhe Biomedical
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma
FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
This randomized phase II trial studies how well modified irinotecan hydrochloride, leucovorin calcium, fluorouracil (FOLFIRI) and veliparib as a second line of therapy work compared to FOLFIRI in treating patients with pancreatic…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02890355
- Testing
- Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis
- Where
- 783 sites in United States
- Volunteers
- 123 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer
RATIONALE: Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy or kill tumor…
- Trial name
- NCT00262808
- Testing
- sargramostim, fluorouracil, leucovorin calcium
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Rochester
Stage IV Colon Cancer, Stage IV Rectal Cancer
High-Dose Cholecalciferol in Treating Patients Receiving Combination Chemotherapy and Bevacizumab as First-Line Therapy For Metastatic Colorectal Cancer
This phase II trial is studying how well giving high-dose cholecalciferol works in treating patients receiving combination chemotherapy and bevacizumab as first-line therapy for metastatic colorectal cancer.
- Trial name
- NCT01198548
- Testing
- leucovorin calcium, bevacizumab, cholecalciferol
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Roswell Park Cancer Institute